Wellington Partners

Wellington Partners is a pan-European venture capital firm established in 1998, with offices in Munich, London, Zurich, and Palo Alto. The firm specializes in early- and growth-stage investments, primarily in technology and life sciences sectors, including digital media, software, electronics & photonics, resource efficiency, and biotech/life sciences. They typically lead financing rounds ranging from €0.5 million to €20 million, with their own commitment reaching up to €15 million, depending on the company's maturity.

The firm's investment strategy focuses on providing outstanding entrepreneurs with the necessary resources to fund their strategies. They proactively source deals and lead or co-lead financing rounds, from early stage to expansion stage and selected PIPE investments (Private Investment in Public Equity). Wellington Partners is committed to offering board-level strategic support to entrepreneurs while they exercise operational control. Together with their global scientific and commercial network, they are in a position to organize financing rounds, accelerate preclinical and clinical development, regulatory approval processes, and drive successful market entry into the most important healthcare markets in Europe, the U.S., and Asia.

Wellington Partners has invested in more than 50 early- and growth-stage life science companies, including Actelion, Definiens, immatics, invendo, MTM Laboratories, Oxford Immunotec, Rigontec, Symetis, and Themis. They have a strong track record with over 20 of their portfolio companies achieving a successful exit or IPO. The firm's team consists of both MDs and PhDs, bringing together a unique combination of passionate and committed people, extensive investment experience, and company-building skills. They are dedicated to supporting entrepreneurs in building successful businesses of exceptional growth.